Loading
Life sciences · Journal article
Pharmaceuticals · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
PRDM16 is a PR domain-containing epigenetic regulator with intrinsic histone methyltransferase activity and scaffolding interactions with corepressor complexes such as CtBP1/2. Beyond its well-established roles in adipose biology, emerging evidence positions PRDM16 as a central node linking chromatin regulation, metabolic control, and cell survival in the kidney, making it a multimodal pharmacological target. In acute kidney injury, PRDM16 functions as an endogenous protective hub that simultaneously suppresses ferroptosis, apoptosis, and pyroptosis through distinct downstream pathways. In chronic and diabetic kidney disease, TGF-β/Smad-driven silencing or promoter hypermethylation of PRDM16 disrupts PGC-1α-dependent mitochondrial integrity and podocyte insulin signaling, offering opportunities for epigenetic reactivation strategies and gene therapy. In clear cell renal cell carcinoma, PRDM16 exhibits a striking duality: epigenetically silenced by CpG island hypermethylation within cancer cells yet upregulated in peritumoral adipocytes to drive a browning-associated, pro-metastatic secretome, defining a unique pharmacological dichotomy that calls for cell-type-selective interventions. This review synthesizes the molecular architecture, isoform diversity, and disease-stage-specific regulation of PRDM16 and evaluates the pharmacological toolset currently available: the expression-inducing natural product formononetin, adenoviral and lentiviral gene delivery systems, and platelet membrane-coated or PLGA-based nanoparticles (PNPs) that enable kidney-targeted delivery. We further discuss key pharmacological challenges, including the need for isoform-selective modulation to avoid oncogenic short-form upregulation, cell-type-specific targeting within the nephron and tumor microenvironment, and the development of pharmacodynamic biomarkers for clinical translation. By integrating mechanistic insights with a drug discovery perspective, this review provides a comprehensive pharmacological framework for targeting PRDM16 to restore renal homeostasis and halt disease progression.